![]() |
|
|
Hyperlipidemia and Atherosclerosis Research Group, Clinical Research Institute of Montréal, Montréal, QC, Canada
2To whom correspondence should be addressed. E-mail: cohnj{at}ircm.qc.ca.
| ABSTRACT |
|---|
|
|
|---|
KEY WORDS: adipose tissue atherosclerosis cholesterol insulin obesity
Adipose tissue is not simply a depot of fat, but is an endocrine organ capable of secreting proteins that can affect whole-body metabolism and homeostasis (1). Several of these proteins [e.g., adiponectin, leptin, plasminogen activator inhibitor-1, apolipoprotein (apo)3 E and apoC-I] have been implicated in the etiology of insulin resistance and atherosclerosis, and may be responsible for the direct link between increased adiposity and cardiovascular disease (2,3).
ApoE and apoC-I are proteins that play a central role in regulating plasma lipid metabolism (4,5). ApoE mediates the uptake of triglyceride-rich lipoproteins (TRL) by hepatic receptors (6), whereas apoC-I has an inhibitory effect (7). The genes for these proteins are adjacent to each other on chromosome 19 within a 45-kb cluster containing the pseudo apoC-I, apoC-IV, and apoC-II genes (8). The majority of plasma apoE and apoC-I is made by the liver. However, a number of tissues are able to produce these proteins, e.g., the brain, spleen, lung, adrenals, ovary, kidney, and muscle (911). Adipose tissue also has the capacity to synthesize apoE and apoC-I. Zechner et al. (12) showed that differentiated mouse 3T3-L1 adipocytes and human adipose tissue biopsies contain apoE mRNA, and they both synthesize and secrete apoE. In 3T3-L1 cells, apoE is expressed in a differentiation-dependent manner; its regulation is related to intracellular free cholesterol levels. Lafitte et al. (13) demonstrated that the nuclear receptors, liver X receptor (LXR)
and LXRß, and their oxysterol ligands are key regulators of adipocyte apoE expression through their interaction with conserved LXR response elements present in multi-enhancer regions ME.1 and ME.2 of the apoE/CI gene cluster.
ApoC-I is a 57-amino acid protein (6.613 kDa) which, like apoE, regulates both systemic and cellular lipid metabolism (5,7). In vitro experiments demonstrated that apoC-I has the capacity to activate lecithin:cholesterol acyltransferase (LCAT), inhibit lipoprotein lipase, hepatic lipase, and phospholipase A2, and inhibit cholesterol ester transfer protein (CETP) activity. ApoC-I also inhibits the binding and/or uptake of triglyceride emulsions or VLDL by the LDL receptor, the LDL-like receptor protein (LRP) and the VLDL receptor (5,7). In mice, overexpression of human apoC-I leads to elevated plasma cholesterol and triglyceride concentrations, impaired hepatic uptake of VLDL particles, reduced whole-body nonesterified fatty acid uptake, and impaired uptake of fatty acids by adipose tissue (1417).
In view of the aforementioned evidence that apoC-I plays an important role in regulating fatty acid uptake by adipose tissue, and given the lack of information pertaining to apoC-I production by adipocytes, we conducted the present study in which we investigated the effect of different tissue culture conditions on the synthesis and secretion of apoC-I and apoE by SW872 liposarcoma cells. The human liposarcoma SW872 cell line was used in previous studies as a human adipocyte cell model (1820). Compared with mouse 3T3-L1 adipocytes, SW872 cells have the advantage of being of human origin and of not requiring an incubation cocktail (e.g., dexamethasone, insulin, and isobutylmethylxanthine) to differentiate into mature adipocytes. SW872 cells, when initially plated, have an immature adipocyte phenotype, and they constitutively express important adipocyte genes such as peroxisome proliferator-activated receptor (PPAR)
, PPAR
, LRP, lipoprotein lipase (LPL), CETP, CD36, and adipsin (20).
| MATERIALS AND METHODS |
|---|
|
|
|---|
Cell culture. SW872 cells were cultured in high-glucose DMEM supplemented with NaHCO3 (3.7 g/L), 100 µmol/L nonessential amino acids, 50 kU/L penicillin, 50 mg/L streptomycin, and 10% FBS, in a humidified incubator (37°C, 5% CO2). Media were replaced every 23 d. Cells (0.5 x 106) were seeded into 6-well plates containing 2 mL of medium. Maturation of SW872 cells was studied by allowing cells to grow for a maximum of 19 d. Media were changed every 48 h and analyses were conducted at 4, 10, and 17 d. Cells reached 100% confluence after 4 d. At each time point, media were removed and cells were washed twice with PBS before further manipulation. Cell maturation was studied in the absence of lipoproteins by incubating cells with 10% LPDS (100 µmol/L nonessential amino acids, 50 kU/L penicillin, 50 mg/L streptomycin). Cells were also studied in the absence of serum, whereby the medium was supplemented with a growth-promoting cocktail containing 15 mmol/L NaHCO3, 15 mmol/L Hepes, 33 µmol/L biotin, 17 µmol/L pantothenate, 0.2 nmol/L triiodothyronine, 1.25 µmol/L bovine insulin, 0.1 mmol/L NaOH, 0.1 µmol/L dexamethasone, 100 µmol/L nonessential amino acids, 50 kU/L penicillin and 50 mg/L streptomycin (individual components from Sigma Chemical). To study the effect of insulin, cells were grown for 7 d postconfluence in FCS-containing medium, washed with PBS, and incubated with either 0, 10, or 1000 nmol/L bovine insulinsupplemented medium (10% FCS) for a subsequent 7 d.
Cells analysis.
Cells were washed with PBS, and total cellular lipids were extracted using three 1-h incubations with 1.0 mL hexane/isopropanol (3:2, v:v). Solvent extracts were centrifuged (10 min at 2000 x g), and supernatants were transferred and dried under nitrogen. Total cholesterol and triglyceride were quantified by enzymatic reaction using reagents from Roche Diagnostics (Indianapolis, IN). Cellular lipid accumulation was also monitored microscopically after lipid staining with Oil Red O (21). Media were collected and apolipoproteins were quantified by a sandwich ELISA (22,23) using goat anti-human polyclonal antibodies obtained from Biodesign International and horseradish peroxidaseconjugated goat anti-human antibodies obtained from Academy Bio-Medical Company. ELISAs were specific for human apolipoproteins, and zero values were obtained when fresh media containing bovine serum were assayed. ApoC-I and apoE detected in cell media therefore represented a measure of secreted apolipoprotein. Re-uptake of human apolipoproteins was negligible because the media contained an excess of bovine apoC-I and apoE provided by the FCS. To quantify cellular apolipoproteins, SW872 cells were washed with PBS, harvested, and dissolved in a lysis buffer (50 mmol/L TRIS-Base, 150 mmol/L KCl and 1% Tween). Cellular apolipoproteins were then quantified by ELISA. To measure total cell proteins, cells were washed with PBS and solubilized using 0.1 mol/L NaOH. Total cell proteins were quantified according to Lowry et al. (24), using bovine serum albumin as a standard. RNA was extracted according to the manufacturers instructions with Trizol obtained from Invitrogen and then quantified using a spectrophotometer. A reverse transcriptase reaction was then carried out and the resultant cDNA was amplified using real-time PCR with the SYBR green mastermix purchased from Qiagen and analyzed with Mx4000 software. S14 (used as a standard), apoC-I, apoE, PPAR
, PPARß, and PPAR
primers were designed using the Primer 3 software (25) and were made by Invitrogen.
Statistics. Values in the text are means ± SEM. One-way ANOVA was performed using SigmaStat 2.0 (Jandel). Data that were not normally distributed were analyzed nonparametrically using Kruskal-Wallis 1-way ANOVA on ranks. Post-hoc multiple comparison tests included Tukeys test (parametric) or Dunns method (nonparametric). Differences were considered significant at P < 0.05.
| RESULTS |
|---|
|
|
|---|
100% more cholesterol and 3 times more triglyceride than when they reached confluence at d 4 (Fig. 1C).
|
mRNA (Fig. 2A). Neither PPAR
nor PPAR
mRNA levels increased significantly with time, although PPAR
mRNA levels were already elevated in confluent cells at 4 d. This was consistent with the fact that SW872 cells resemble differentiated adipocytes and express other functionally important adipocyte genes including LRP, LPL, CETP, and CD36 (20). At d 17, SW872 cells had significantly higher LRP mRNA levels (0.46 ± 0.05 vs. 0.19 ± 0.03, P < 0.001) and higher LPL mRNA levels (0.05 ± 0.01 vs. 0.04 ± 0.01, P < 0.01) compared with d 4. Cellular levels of apoE mRNA increased significantly during cell maturation; however, levels of apoC-I mRNA decreased significantly (Fig. 2B).
|
|
|
3 times greater than that occurring with standard medium (Fig 5B). Cellular and medium apoC-I and apoE increased significantly (Fig. 5C and D), and this increase was also greater in magnitude than that observed in the presence of FCS-containing medium (Fig. 3A and B).
|
|
| DISCUSSION |
|---|
|
|
|---|
1 molecule of apoC-I for every 9 molecules of apoE, and the medium contained
1 molecule of apoC-I for every 7 molecules of apoE. When SW872 cells were allowed to mature for 17 d in culture in the presence of 10% FCS, cellular lipid accumulation (100% increase in cholesterol, 3-fold increase in triglyceride) was associated with a significant increase in both cellular and medium levels of apoC-I and apoE. Increase in the synthesis and secretion of apoE was greater than that of apoC-I (Fig. 3) and after 17 d in culture, the molar ratio of apoE:apoC-I in the cell was 21.6 ± 2.6 and in the medium was 13.3 ± 1.6. Similar changes were observed when cells were incubated with lipoprotein-deficient serum (Fig. 4) or when cells were incubated without serum (Fig. 5), demonstrating that increased production of both apoC-I and apoE was closely linked to the accumulation of cellular cholesterol and triglyceride, independent of the presence or absence of lipid in the medium.
Zechner et al. (12) showed previously that differentiation of mouse 3T3-L1 preadipocytes into mature adipocytes results in increased production of apoE. More recently, gene chip experiments showed that apoC-I expression is also significantly increased during adipocyte differentiation (26,27). The present results extend these observations by showing that human SW872 cells, which already display a differentiated adipocytic phenotype, i.e., they express measurable amounts of PPAR
mRNA (Fig. 2) and other adipocytic genes in the basal state (20), increase their apoE production as they accumulate lipid. Cell maturation is also associated with an increase in synthesis and secretion of apoC-I, independent of any additional increase in PPAR
mRNA (Fig. 2). These data suggest that increased apoC-I and apoE production is not only a feature of adipocyte differentiation, but is a characteristic of the transformation of SW872 cells from immature to mature adipocytes. ApoC-I and/or apoE may play an important role in the regulation of adipocyte lipid accumulation, consistent with their documented effects on lipid uptake and/or efflux in other cell types. For example, apoC-I is an inhibitor of lipoprotein receptors of the LDL-receptor family (5,7), and has an inhibitory effect on the tissue uptake of FFA (16,17). ApoE might be important in regulating receptor-mediated uptake of adipocyte lipid (4), as supported by the observation that adipose tissue mass is significantly reduced in obese ob/ob mice that are also made deficient in apoE (28). ApoE can also stimulate LRP-mediated selective uptake of HDL cholesteryl esters by adipocytes (20). On the other hand, newly synthesized endogenous apoE mediates cholesterol efflux from macrophages (29,30), and it is possible that apoE plays a similar role in maturing adipocytes. Clearly, these different possibilities can only be substantiated by future experiments.
The apoC-I and apoE genes are adjacent to each other on the same chromosome (8) and are regulated by common control regions (13,31,32). Thus, apoC-I and apoE gene expression in the liver is driven by 2 enhancer regions, hepatic control regions (HCR) 1 and 2, which are
9 and
20 kb, respectively, downstream of the apoC-I gene (32,33). Macrophage and adipose tissue apoC-I and apoE gene expression is in turn directed by 2 multienhancer regions (ME.1 and ME.2) that are situated on either side of the apoC-I gene (34). Furthermore, 2 LXR response elements located within ME.1 and ME.2 appear to be responsible for the induction of macrophage apoC-I and apoE gene expression by ligands for LXR and retinoid X receptor (35). On the basis of these results, we initially hypothesized that any change in the level of apoC-I mRNA would be mimicked by a similar change in apoE mRNA. Furthermore, we expected that changes in apoC-I or apoE mass in maturing SW872 cells would be mimicked by similar changes in mRNA levels. In fact, parallel changes in apoC-I and apoE mRNA were not observed in either the maturation experiments or those with insulin. Increased levels of apoE mRNA, but not apoC-I mRNA, were consistently observed in cells incubated in the presence or absence of extracellular lipids (Fig. 2Band 5B), whereas insulin treatment was associated with a decrease in apoC-I mRNA, but not apoE mRNA (Fig. 6A). These data provide clear evidence for differential regulation of the apoC-I and apoE genes in SW872 cells, and suggest the presence of regulatory elements in the apoE/apoC-I/apoC-II gene cluster that are specific for individual apolipoproteins. At the same time, our data suggest that the production of these apolipoproteins was regulated post-transcriptionally, as evidenced by the increase in apoC-I protein in the absence of increased apoC-I mRNA during maturation (e.g., Fig. 5), and the decrease in secreted apoE in the absence of any change in apoE mRNA during insulin treatment (Fig. 6). This is consistent with the post-transcriptional regulation of apoC-I and apoE production in human HepG2 cells (36,37) and of apoE production in macrophages (38,39). Post-translational degradation of apoC-I and apoE by specific proteases has been shown to occur in hepatocytes and macrophages (36); however, it remains to be determined whether similar proteases are responsible for regulating levels of apoC-I and apoE secretion in human adipocytes.
Insulin stimulates the uptake of glucose and FFA by adipose tissue. It can increase LPL activity, induce the translocation of fatty acid transport proteins to the surface of adipocytes, and stimulate adipocyte lipid accumulation (40,41). In view of the relation observed between lipid accumulation and increased apoC-I and apoE production in SW872 cells during maturation, we expected that insulin treatment would further stimulate apoC-I and apoE production. Surprisingly, however, long-term incubation of cells with insulin caused a decrease in apoC-I and apoE secretion, concomitant with a decrease in apoC-I mRNA, although not apoE mRNA (Fig. 6). These data suggest that insulin by itself does not induce transcription of the apoC-I or apoE gene in adipocytes, in agreement with results obtained with cultured rat hepatocytes (42) and human hepatoma cells (43,44), in which insulin had no effect on apoE mRNA levels, but a small and reproducible lowering effect on apoE secretion. From these results, it can also be deduced that the ability of the serum-free, growth-promoting medium to increase apoE and apoC-I production in SW872 cells (Fig. 5) was probably not a direct consequence of its high insulin concentration (1.25 µmol/L).
In conclusion, the results of the present study demonstrate that SW872 liposarcoma cells synthesize and secrete both apoC-I and apoE. When these cells are incubated for an extended period of time in the presence of 10% FCS, they accumulate cholesterol and triglyceride, and produce significantly increased amounts of these apolipoproteins. Lipid accumulation and increased apoC-I and apoE production can also occur over time in the absence of extracellular lipids. In addition, evidence was obtained for the differential regulation of apoC-I and apoE production at the transcriptional as well as the post-transcriptional level, and long-term insulin treatment had an inhibitory rather than a stimulatory effect on apoC-I and apoE production. These results suggest that apoC-I and apoE play a role in the maturation of human adipocytes and may be important in mediating or regulating cell lipid accumulation. Further work is required to define this regulatory function and determine whether these apolipoproteins are essential for adipocyte maturation.
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
3 Abbreviations used: apo, apolipoprotein; CETP, cholesterol ester transfer protein; FCS, fetal calf serum; LCAT, lecithin cholesterol acyltransferase; LPDS, lipoprotein-deficient serum; LPL, lipoprotein lipase; LRP, LDL-like receptor protein; LXR, liver X receptor; PPAR, peroxisome proliferator-activated receptor; TRL, triglyceride-rich lipoprotein(s). ![]()
Manuscript received 17 June 2004. Initial review completed 29 June 2004. Revision accepted 17 August 2004.
| LITERATURE CITED |
|---|
|
|
|---|
1. Spiegelman, B. M. & Flier, J. S. (2001) Obesity and the regulation of energy balance. Cell 104:531-543.[Medline]
2. Grundy, S. M. (2004) Obesity, metabolic syndrome, and cardiovascular disease. J. Clin. Endocrinol. Metab. 89:2595-2600.
3. Engstrom, G., Hedblad, B., Stavenow, L., Jonsson, S., Lind, P., Janzon, L. & Lindgarde, F. (2004) Incidence of obesity-associated cardiovascular disease is related to inflammation-sensitive plasma proteins. A population-based cohort study. Arterioscler. Thromb. Vasc. Biol. 24:1498-1502.
4. Mahley, R. W. & Huang, Y. (1999) Apolipoprotein E: from atherosclerosis to Alzheimers disease and beyond. Curr. Opin. Lipidol. 10:207-217.[Medline]
5. Shachter, N. S. (2001) Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr. Opin. Lipidol. 12:297-304.[Medline]
6. Cooper, A. D. (1997) Hepatic uptake of chylomicron remnants. J. Lipid Res. 38:2173-2192.[Abstract]
7. Jong, M. C., Hofker, M. H. & Havekes, L. M. (1999) Role of apoCs in lipoprotein metabolism. Functional differences between apoC1, apoC2, and apoC3. Arterioscler. Thromb. Vasc. Biol. 19:472-484.
8. Lauer, S., Walker, D., Elshourbagy, N. A., Reardon, C. A., Levy-Wilson, B. & Taylor, J. M. (1988) Two copies of the human apolipoprotein C-I gene are linked closely to the apolipoprotein E gene. J. Biol. Chem. 263:7277-7286.
9. Knott, T. J., Robertson, M. E., Priestly, M., Wallis, S. & Scott, J. (1984) Characterization of mRNAs encoding the precursor for human apolipoprotein CI. Nucleic Acids Res. 12:3909-3915.
10. Newman, T. C., Dawson, P. A., Rudel, L. L. & Williams, D. L. (1985) Quantitation of apolipoprotein E mRNA in the liver and peripheral tissues of nonhuman primates. J. Biol. Chem. 260:2452-2457.
11. Elshourbagy, N. A., Liao, W. S., Mahley, R. W. & Taylor, J. M. (1985) Apolipoprotein E mRNA is abundant in the brain and adrenals, as well as in the liver, and is present in other peripheral tissues of rats and marmosets. Proc. Natl. Acad. Sci. U.S.A. 82:203-207.
12. Zechner, R., Moser, R., Newman, T. C., Fried, S. K. & Breslow, J. L. (1991) Apolipoprotein E gene expression in mouse 3T3L1 adipocytes and human adipose tissue and its regulation by differentiation and lipid content. J. Biol. Chem. 266:10583-10588.
13. Laffitte, B. A., Repa, J. J., Joseph, S. B., Wilpitz, D. C., Kast, H. R., Mangelsdorf, D. J. & Tontonoz, P. (2001) LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc. Natl. Acad. Sci. U.S.A. 98:507-512.
14. Shachter, N. S., Ebara, T., Ramakrishnan, K., Steiner, G., Breslow, J. L., Ginsberg, H. N. & Smith, J. D. (1996) Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein Cl. J. Clin. Investig. 98:846-855.[Medline]
15. Jong, M. C., Gijbels, M. J., Dahlmans, V. E., Gorp, P. J., Koopman, S. J., Ponec, M., Hofker, M. H. & Havekes, L. M. (1998) Hyperlipidemia and cutaneous abnormalities in transgenic mice overexpressing human apolipoprotein C1. J. Clin. Investig. 101:145-152.[Medline]
16. Koopmans, S. J., Jong, M. C., Dahlmans, V.E.H., Pijl, H., Radder, J. K., Frolich, M. & Havekes, L. M. (2001) Hyperlipidaemia is associated with increased insulin-mediated glucose metabolism, reduced fatty acid metabolism and normal blood pressure in transgenic mice overexpressing human apolipoprotein C1. Diabetologia 44:437-443.[Medline]
17. Jong, M. C., Voshol, P. J., Muurling, M., Dahlmans, V. E., Romijn, J. A., Pijl, H. & Havekes, L. M. (2001) Protection from obesity and insulin resistance in mice overexpressing human apolipoprotein C1. Diabetes 50:2779-2785.
18. Richardson, M. A., Berg, D. T., Johnston, P. A., McClure, D. & Grinnell, B. W. (1996) Human liposarcoma cell line, SW872, secretes cholesteryl ester transfer protein in response to cholesterol. J. Lipid Res. 37:1162-1166.[Abstract]
19. Izem, L. & Morton, R. E. (2001) Cholesteryl ester transfer protein biosynthesis and cellular cholesterol homeostasis are tightly interconnected. J. Biol. Chem. 276:26534-26541.
20. Vassiliou, G., Benoist, F., Lau, P., Kavaslar, G. N. & McPherson, R. (2001) The low density lipoprotein receptor-related protein contributes to selective uptake of high density lipoprotein cholesteryl esters by SW872 liposarcoma cells and primary human adipocytes. J. Biol. Chem. 276:48823-48830.
21. Von Goor, H., Gerrits, P. O. & Groud, J. (1986) The application of lipid-soluble stains in plastic-embedded sections. Histochemistry 85:251-253.[Medline]
22. Cohn, J. S., Tremblay, M., Amiot, M., Bouthillier, D., Roy, M., Genest, J., Jr & Davignon, J. (1996) Plasma concentration of apolipoprotein E in intermediate-sized remnant-like lipoproteins in normolipidemic and hyperlipidemic subjects. Arterioscler. Thromb. Vasc. Biol. 16:149-159.
23. Cohn, J. S., Tremblay, M., Batal, R., Jacques, H., Veilleux, L., Rodriguez, R., Bernier, L., Mamer, O. & Davignon, J. (2002) Plasma kinetics of apoC-I in VLDL and HDL in normolipidemic and hypertriglyceridemic subjects. J. Lipid Res. 43:1680-1687.
24. Lowry, O. H., Rosebrough, N. J., Farr, A. L. & Randall, R. J. (1951) Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:265-275.
25. Primer 3 Software Whitehead Institute for Biomedical Research (http://www-genome.wi.mit.edu/genome software/other/primer3.html) [last accessed December 2003].
26. Ross, S. E., Erickson, R. L., Gerin, I., DeRose, P. M., Bajnok, L., Longo, K. A., Misek, D. E., Kuick, R., Hanash, S. M., Atkins, K. B., Andresen, S. M., Nebb, H. I., Madsen, L., Kristiansen, K. & MacDougald, O. A. (2002) Microarray analyses during adipogenesis: understanding the effects of Wnt signaling on adipogenesis and the roles of liver X receptor
in adipocyte metabolism. Mol. Cell Biol. 22:5989-5999.
27. Seo, J. B., Moon, H. M., Kim, W. S., Lee, Y. S., Jeong, H. W., Yoo, E. J., Ham, J., Kang, H., Park, M-G., Steffensen, K. R., Stulnig, T. M., Gustafsson, J-A., Park, S. D. & Kim, J. B. (2004) Activated liver X receptors stimulate adipocyte differentiation through induction of peroxisome proliferator-activated receptor
expression. Mol. Cell. Biol. 24:3430-3444.
28. Chiba, T., Nakazawa, T., Yui, K., Kaneko, E. & Shimokado, K. (2003) VLDL induces adipocyte differentiation in apoE-dependent manner. Arterioscler. Thromb. Vasc. Biol. 23:1423-1429.
29. Lin, C. Y., Duan, H. & Mazzone, T. (1999) Apolipoprotein E-dependent cholesterol efflux from macrophages: kinetic study and divergent mechanisms for endogenous versus exogenous apolipoprotein E. J. Lipid Res. 40:1618-1627.
30. Lin, C. Y., Huang, Z. H. & Mazzone, T. (2001) Interaction with proteoglycans enhances the sterol efflux produced by endogenous expression of macrophage apoE. J. Lipid Res. 42:1125-1133.
31. Simonet, W. S., Bucay, N., Pitas, R. E., Lauer, S. J. & Taylor, J. M. (1991) Multiple tissue-specific elements control the apolipoprotein E/C-I gene locus in transgenic mice. J. Biol. Chem. 266:8651-8654.
32. Simonet, W. S., Bucay, N., Lauer, S. J. & Taylor, J. M. (1993) A far-downstream hepatocyte-specific control region directs expression of the linked human apolipoprotein E and C-I genes in transgenic mice. J. Biol. Chem. 268:8221-8229.
33. Allan, C. M., Taylor, S. & Taylor, J. M. (1997) Two hepatic enhancers, HCR. 1 and HCR. 2, coordinate the liver expression of the entire human apolipoprotein E/C-I/C-IV/C-II gene cluster. J. Biol. Chem. 272:29113-29119.
34. Shih, S. J., Allan, C., Grehan, S., Tse, E., Moran, C. & Taylor, J. M. (2000) Duplicated downstream enhancers control expression of the human apolipoprotein E gene in macrophages and adipose tissue. J. Biol. Chem. 275:31567-31572.
35. Mak, P. A., Laffitte, B. A., Desrumaux, C., Joseph, S. B., Curtiss, L. K., Mangelsdorf, D. J., Tontonoz, P. & Edwards, P. A. (2002) Regulated expression of the apolipoprotein E/C-I/C-IV/C-II gene cluster in murine and human macrophages. A critical role for nuclear liver X receptors alpha and beta. J. Biol. Chem. 277:31900-31908.
36. Wenner, C., Lorkowski, S., Engel, T. & Cullen, P. (2001) Apolipoprotein E in macrophages and hepatocytes is degraded via the proteasomal pathway. Biochem. Biophys. Res. Commun. 282:608-614.[Medline]
37. Bouchard, C., Dubuc, G., Davignon, J., Bernier, L. & Cohn, J. S. () Post-transcriptional regulation of apoC-I synthesis and secretion in human HepG2 cells. Atherosclerosis (in press).
38. Duan, H., Lin, C. Y. & Mazzone, T. (1997) Degradation of macrophage apoE in a nonlysosomal compartment. Regulation by sterols. J. Biol. Chem. 272:31156-31162.
39. Duan, H., Gu, D. & Mazzone, T. (2000) Sterols and inhibitors of sterol transport modulate the degradation and secretion of macrophage ApoE: requirement for the C-terminal domain. Biochim. Biophys. Acta 1484:142-150.[Medline]
40. Stahl, A., Evans, J. G., Pattel, S., Hirsch, D. & Lodish, H. F. (2002) Insulin caused fatty acid transport protein translocation and enhanced fatty acid uptake in adipocytes. Dev. Cell 2:477-488.[Medline]
41. Rondinone, C. M., Trevillyan, J. M., Clampit, J., Gum, R. J., Berg, C., Kroeger, P., Frost, L., Zinker, B. A., Reilly, R., Ulrich, R., Butler, M., Monia, B. P., Jirousek, M. R. & Waring, J. F. (2002) Protein tyrosine phosphatase 1B reduction regulates adiposity and expression of genes involved in lipogenesis. Diabetes 51:2405-2411.
42. Kim, M. H., Nakayama, R., Manos, P., Tomlinson, J. E., Choi, E., Ng, J. D. & Holten, D. (1989) Regulation of apolipoprotein E synthesis and mRNA by diet and hormones. J. Lipid Res. 30:663-671.[Abstract]
43. Dashti, N., Williams, D. L. & Alaupovic, P. (1989) Effects of oleate and insulin on the production rates and cellular mRNA concentrations of apolipoproteins in HepG2 cells. J. Lipid Res. 30:1365-1373.[Abstract]
44. Ogbonna, G., Theriault, A. & Adeli, K. (1993) Hormonal regulation of human apolipoprotein E gene expression in HepG2 cells. Int. J. Biochem. 25:635-640.[Medline]
This article has been cited by other articles:
![]() |
K. Ishimoto, H. Nakamura, K. Tachibana, D. Yamasaki, A. Ota, K.-i. Hirano, T. Tanaka, T. Hamakubo, J. Sakai, T. Kodama, et al. Sterol-mediated Regulation of Human Lipin 1 Gene Expression in Hepatoblastoma Cells J. Biol. Chem., August 14, 2009; 284(33): 22195 - 22205. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-H. Yu and H. N. Ginsberg Adipocyte Signaling and Lipid Homeostasis: Sequelae of Insulin-Resistant Adipose Tissue Circ. Res., May 27, 2005; 96(10): 1042 - 1052. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||